| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
I am a very cynical man, but even my black heart was softened a little by the efforts of companies big and small in response to the recent carnage in Louisiana, Mississippi, Alabama, and Florida. For an industry that is almost universally maligned and distrusted, it was good to see the pharmaceutical and biotech communities (both brand name and generic) come together to support the rescue and welfare efforts of the victims of Hurricane Katrina.
 
While there are bound to be those who will see the donations of money and products as little more than a public relations ploy, I want to be one of the first to rise from my seat and applaud these efforts. Sadly, it is usually only in times of crisis that we see of what people and corporations are made.
 
Many companies are working through various pharmacies, like Walgreen's, Rite-Aid, Wal-Mart, and Sam's Clubs, to ensure that people get the medicines they so desperately need. Others have chosen to work through relief agencies like the American Red Cross, Salvation Army, United Way, and local governments to help evacuees and refugees get back to a sense health and safety. According to PhRMA, as of September 7, 2005, companies had donated nearly $45 million in product and cash to these efforts.
 
Thanks to each of you for your efforts to relieve suffering both in the United States and elsewhere.
 
Randall C Willis
Executive Editor

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue